Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364346 | 1.00 | MAPT (0.55) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364762 | 0.94 | MAPT (0.62) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364778 | 0.94 | MAPT (0.62) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364216 | 0.90 | MAPT (0.61) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364210 | 0.90 | MAPT (0.61) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364242 | 0.90 | MAPT (0.61) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364269 | 0.89 | MAPT (0.63) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364298 | 0.89 | MAPT (0.63) | MAPTL3MBTL1ATMCYP2C19CYP3A4 | |
| SCHEMBL18364164 | 0.83 | MAPT (0.49) | MAPTL3MBTL1ATMANPEPPPID | |
| SCHEMBL18364278 | 0.82 | EPHX2 (0.47) | MAPTCYP2C19NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | MAPT 8/4885L3MBTL1 4164/4885ATM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.